NASDAQ:IVVD Invivyd Q2 2026 Earnings Report $0.82 +0.01 (+0.69%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$0.84 +0.02 (+1.93%) As of 10/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Invivyd EPS ResultsActual EPS-$0.14Consensus EPS -$0.11Beat/MissMissed by -$0.03One Year Ago EPSN/AInvivyd Revenue ResultsActual Revenue$14.29 millionExpected Revenue$14.40 millionBeat/MissMissed by -$111.00 thousandYoY Revenue GrowthN/AInvivyd Announcement DetailsQuarterQ2 2026Date8/13/2026TimeAfter Market ClosesConference Call DateThursday, August 13, 2026Conference Call Time4:00PM ETUpcoming EarningsInvivyd's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Invivyd Earnings HeadlinesInvivyd, Inc. Announces Positive Topline Results from Liberty Phase 3 Study Demonstrating Vyd2311 Safety and Tolerability Superior to Mrna-Based Covid-19 VaccineSeptember 30, 2026 | marketscreener.comMInvivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 VaccineSeptember 30, 2026 | marketscreener.comMElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt without major changes. As former head of the Department of Government Efficiency under President Trump, Musk saw firsthand how looming spending cuts could rattle markets and squeeze 401ks, IRAs, and TSPs. A preserved IRS provision may help everyday investors shield their retirement savings before the next wave of volatility hits.October 4 at 1:00 AM | American Hartford Gold (Ad)Invivyd's VYD2311 Meets Primary Goals in Head-to-Head mRNA Vaccine TrialSeptember 29, 2026 | finance.yahoo.comInvivyd reports positive phase 3 LIBERTY results for VYD2311 and plans accelerated approval submissionSeptember 29, 2026 | msn.comInvivyd drops after delaying late-stage trial data for COVID therapySeptember 29, 2026 | seekingalpha.comSee More Invivyd Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Invivyd? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Invivyd and other key companies, straight to your email. Email Address About InvivydInvivyd (NASDAQ:IVVD) is a clinical-stage biopharmaceutical company focused on developing antibody-based medicines designed to prevent and treat viral diseases. The company’s approach is intended to provide durable protection against rapidly evolving viruses by using engineered monoclonal antibodies that can be updated as pathogens change. Invivyd’s leading product is pemivibart, marketed in the United States under the brand name PEMGARDA. The product received emergency use authorization from the U.S. Food and Drug Administration for pre-exposure prophylaxis against COVID-19 in certain moderately to severely immunocompromised individuals for whom vaccination is not expected to provide adequate protection. Invivyd is also advancing additional antibody candidates for infectious disease indications. The company was founded as Adagio Therapeutics and changed its name to Invivyd in 2023. Based in Waltham, Massachusetts, Invivyd conducts research and clinical development activities intended to support the availability of its antibody therapies in the United States and other markets. The company is led by Mark J. Esser, Ph.D., who serves as president and chief executive officer.View Invivyd ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the Test Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
